GlassScriptPhysician profile
Andrew J Mcdowell
NPI 1376947432
$4,089.51
in general payments reported to CMS, 2019-2025
23 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.23 · 2024: $410 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,981 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,981.29 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.97 | 2024-2025 | |
| Madrigal Pharmaceuticals | $578.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $506.52 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $418.86 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $343.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $304.84 | 2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $300.68 | 2025 | Voquezna |
| Lilly USA, LLC | $203.00 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $137.66 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $102.42 | 2025 | |
| Ironwood Pharmaceuticals, INC | $97.83 | 2024-2025 | |
| Amgen INC. | $88.90 | 2024-2025 | Uplizna |
| Pfizer INC. | $87.12 | 2025 | |
| Qol Medical, LLC | $64.43 | 2024-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $58.47 | 2025 | Zenpep |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.88 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medtronic, INC. | $31.23 | 2022 | |
| Organon LLC | $24.09 | 2025 | Hadlima, Renflexis |
| Novo Nordisk INC | $23.84 | 2025 | Wegovy |
| Biocon Biologics INC | $20.78 | 2025 | Yesintek |
| Braintree Laboratories, INC. | $17.80 | 2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.06 | 2025 | Relistor |
| Invivyd INC | $14.57 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.